Feasibility and Acceptability of a Virtual 'Coping With Brain Fog' Intervention for Young Adults With Cancer

May 20, 2022 updated by: Sapna Oberoi, University of Manitoba

Feasibility and Acceptability of a Virtual 'Coping With Brain Fog' Intervention for Adolescents and Young Adults With Cancer

Cancer-related cognitive problems, also known as "brain fog", have a significant impact on patients with cancer and cancer survivors. Previous studies indicate that cancer and cancer treatments can negatively affect memory, attention and thinking abilities. Adolescents and young adults (AYAs) are individuals with a cancer diagnosis, who are currently between 18 to 40 years old. These individuals are especially vulnerable to brain fog symptoms due to the effect these symptoms have on their education, employment, health behaviors, mental health, and social relationships. There is a clear need for programming directed at brain fog symptoms among AYAs with cancer diagnoses. The 'Coping with Brain Fog' program, developed by Maximum Capacity Inc., is an eight-week group program that has been designed to educate patients about their brain fog symptoms and develop strategies to manage these symptoms. In this study the investigators will aim to determine the feasibility of adapting the 'Coping with Brain Fog' program to the virtual setting for AYAs with cancer during the COVID-19 pandemic. The investigators will also aim to explore the efficacy of the program on cognitive functioning and symptoms of anxiety, depression and fatigue. This study is an important step towards finding ways to treat brain fog symptoms in cancer patients, and could help guide future studies and programs.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Background: Cancer-related cognitive deficits, also known as "brain fog", are a well-established morbidity among patients with cancer and cancer survivors. Associations between cancer or cancer treatment with difficulties in short-term and working memory, attention, processing speed, verbal fluency, and executive function have been previously described. Adolescents and young adults (AYA) are individuals who have had a cancer diagnosis and are currently between 18 to 40 years of age. Mitigating cognitive symptoms in the AYA population is especially important, as these cognitive symptoms affect education and employment, health behaviors, mental health, and social relationships. Further, as more AYAs with cancer survive their cancer and live into adulthood, improving their quality of life is even more vital. There is a clear need for programming directed at brain fog symptoms among AYAs with a cancer diagnosis.

Objective: The primary objective of this study is to determine the feasibility and acceptability/satisfaction of a virtual 'Coping with Brain Fog' intervention to AYAs with cancer during the COVID-19 pandemic. Secondary objectives of the study are to determine the preliminary effect of the intervention on the cognitive functioning and symptoms of distress (anxiety/depression/fatigue) of AYAs with cancer.

Methods: This prospective pilot study will involve an 8-week virtual "Coping with Brain Fog" program, with one 90-minutes session per week. The 'Coping with Brain Fog' program, developed by Maximum Capacity Inc., has been designed as an in-person group program to educate participants about brain fog and help them enhance their cognition and overall wellbeing. Sessions are designed to enhance memory, task management, and psychological wellbeing skills. Sessions will be delivered over Zoom in a group setting by a Master's-prepared registered social worker and AYA psychosocial oncology clinician at CancerCare Manitoba. Individuals who are between the ages of 18-40 and are (a) diagnosed with any type or stage of cancer, (b) seeking intervention for self-reported symptoms of brain fog (such as poor memory, mental slowness, or task insufficiency), and (c) currently living in Manitoba, Northwestern Ontario or Nunavut, will be eligible for this study. Before starting the intervention, the study participants will be sent a survey link to collect background patient information and measure self-reported cognitive function and symptoms of distress. The participants will also complete a post-intervention questionnaire to measure self-reported cognitive function, symptoms of distress, and satisfaction within one week of completing the intervention and at 6-8 weeks after the intervention. Semi-structured exit phone interviews will be conducted with the participants within two weeks of completing the intervention to collect their narrative feedback and experiences with the intervention.

Significance: This pilot project will help determine the feasibility and acceptability/satisfaction of a virtual 'Coping with Brain Fog' program and measure its preliminary effects on cognitive function and symptoms of distress among AYAs with cancer.

Study Type

Interventional

Enrollment (Anticipated)

12

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3E 0V9
        • CancerCare Manitoba

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 18-40 years
  • Diagnosed with any type or stage of cancer
  • Seeking intervention for self-reported symptoms of brain fog (such as poor memory, mental slowness, or task insufficiency)
  • Must be currently living in Manitoba, Nunavut or Northwest Ontario
  • Must be able to attend eight virtual sessions of the 'Coping with Brain Fog' intervention
  • Must have reliable access to the internet and the audio-visual platform Zoom
  • Should also be able to read, speak and write English (as the sessions will be conducted in English)

Exclusion Criteria:

  • Age younger than 18 or older than 40 years at the time of enrollment
  • Must not have a previously diagnosed severe intellectual disability (self-reported by the participants)
  • Should not be receiving any new interventions to enhance their cognitive function during the period of this study
  • Must attend the first two sessions and should not miss two consecutive sessions (if a participant misses two consecutive sessions due to extenuating circumstances, they will be encouraged to withdraw from the group and be prioritized on the wait-list for the next brain fog group)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: "Coping with Brain Fog" intervention
Behavioral: 'Coping with Brain Fog' program
The proposed intervention is an 8-week 'Coping with Brain Fog' program for cancer survivors, adapted for AYAs with cancer, with one 90-minute group session per week. The intended group size for the program is 8-12 participants. The program was developed to be delivered in person, however for the purposes of this study it will be conducted in a virtual setting. The overall goals of the program are to educate participants about cancer-related brain fog and enhance their cognitive function and wellbeing. To accomplish this, the program is segmented into three main components: memory skills, task management, and psychological wellbeing. For each component, participants are systematically introduced to evidence-based strategies to cumulatively build a repertoire of cognitive tools designed to reduce the impact of cancer-related brain fog. The program uses a manual and participant materials that are copyrighted by Maximum Capacity Inc.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adherence
Time Frame: Adherence will be assessed at the end of the 8-week intervention.
The investigators will measure the adherence to the intervention by measuring attendance at the weekly sessions. The intervention will be considered feasible if 60% of participants do not miss the first two sessions and any two consecutive sessions.
Adherence will be assessed at the end of the 8-week intervention.
Participant Satisfaction - Client Satisfaction Questionnaire
Time Frame: Participant Satisfaction will be measured at the end of the 8-week intervention.
The participants' satisfaction with the program will be measured using The Client Satisfaction Questionnaire (CSQ), an 8-item self-report scale which will be administered at the end of the intervention to assess the participant satisfaction. Each item on this scale is scored from 1 to 4, generating a total score ranging from 8 to 32. A total score of 8-20 indicates low satisfaction, whereas total scores of 21-26 and 27-32 indicate medium and higher satisfaction, respectively.
Participant Satisfaction will be measured at the end of the 8-week intervention.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Perceived Cognitive Functioning - Functional Assessment of Cancer Therapy-Cognitive Function Scale
Time Frame: The investigators will measure perceived cognitive functioning before, one week after, and 6-8 weeks after the intervention.
The investigators will measure perceived cognitive functioning before and after the intervention using the Functional Assessment of Cancer Therapy (FACT)-Cognitive Function Scale, a 37-item self-report scale, which will be administered to measure subscales of perceived cognitive impairments, impact of perceived cognitive impairments on quality of life, comments from others, and perceived cognitive abilities. Each item on the subscales is scored from 0 to 4, to generate a total score for each subsection. These subscale scores will be aggregated to give a final score between 0-20, with a higher score being associated with better quality of life.
The investigators will measure perceived cognitive functioning before, one week after, and 6-8 weeks after the intervention.
Perceived Cognitive Functioning - Cancer Distress Scales for Adolescents and Young Adults
Time Frame: The investigators will measure perceived cognitive functioning before, one week after, and 6-8 weeks after the intervention.
The investigators will measure perceived cognitive functioning before and after the intervention using the Cognitive component of the Cancer Distress Scales for Adolescents and Young Adults (CDS-AYA), an 8-item self-report scale, which will be administered before and at the end of the intervention to measure distress related to cognitive problems. Each item on this scale is scored from 0 to 3 to generate a total score between 0-24. Raw sum scores are transformed to a score from 0 (best) to 100 (worst), with a higher score reflecting more distress.
The investigators will measure perceived cognitive functioning before, one week after, and 6-8 weeks after the intervention.
Symptoms of Distress and Fatigue - Anxiety
Time Frame: The investigators will measure symptoms of distress before, one week after, and 6-8 weeks after the intervention.
The investigators will evaluate anxiety using the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 - Anxiety 8a, an 8-item self-report scale. Each item on the form is scored from 0 (never) to 5 (always). Scores on each item are summed to determine a raw score, which is converted to a standardized T-score with a mean of 50 and a standard deviation (SD) of 10, with a higher score reflecting greater anxiety.
The investigators will measure symptoms of distress before, one week after, and 6-8 weeks after the intervention.
Symptoms of Distress and Fatigue - Depression
Time Frame: The investigators will measure symptoms of distress before, one week after, and 6-8 weeks after the intervention.
The investigators will evaluate depression using the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 - Depression 8b, an 8-item self-report scale. Each item on the form is scored from 0 (never) to 5 (always). Scores on each item are summed to determine a raw score, which is converted to a standardized T-score with a mean of 50 and a standard deviation (SD) of 10, with a higher score reflecting greater depression.
The investigators will measure symptoms of distress before, one week after, and 6-8 weeks after the intervention.
Symptoms of Distress and Fatigue - Fatigue
Time Frame: The investigators will measure symptoms of distress before, one week after, and 6-8 weeks after the intervention.
The investigators will evaluate fatigue using the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 - Fatigue 8a, an 8-item self-report scale. Each item on the form is scored from 0 (not at all/never) to 5 (very much/always). Scores on each item are summed to determine a raw score, which is converted to a standardized T-score with a mean of 50 and a standard deviation (SD) of 10, with a higher score reflecting greater fatigue.
The investigators will measure symptoms of distress before, one week after, and 6-8 weeks after the intervention.
Participant experience with the program using semi-structured exit interview
Time Frame: Exit interviews will occur at the end of the 8-week intervention.
The semi-structured interview conducted at the end of the intervention will explore participants' experience with the program and satisfaction
Exit interviews will occur at the end of the 8-week intervention.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Manitoba

Collaborators

CancerCare Manitoba

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2021

Primary Completion (Actual)

March 31, 2022

Study Completion (Anticipated)

October 31, 2022

Study Registration Dates

First Submitted

October 16, 2021

First Submitted That Met QC Criteria

October 29, 2021

First Posted (Actual)

November 10, 2021

Study Record Updates

Last Update Posted (Actual)

May 23, 2022

Last Update Submitted That Met QC Criteria

May 20, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AYABF2021P

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Clinical Trials on 'Coping with Brain Fog' program

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe